Thursday , November 23 2017
Home / Conditions / Type 2 Diabetes / “Synjardy” Approved for Type 2 Diabetes

“Synjardy” Approved for Type 2 Diabetes

Single-tablet approach hoped to boost treatment compliance and help patients better manage condition..

Synjardy contains empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin, a biguanide. It is not for the treatment of type 1 diabetes or diabetic ketoacidosis.

The drug label contains a boxed warning on the risk of lactic acidosis during treatment with Synjardy. Lactic acidosis is a serious metabolic complication that can occur due to metformin accumulation during treatment with the therapy. It will be supplied as 5mg/500mg, 5mg/1000mg, 12.5mg/500mg, and 12.5mg/1000mg strength tablets in 60- and 180-count bottles.

The pill’s two components have very different modes of action: empagliflozin is a sodium glucose co-transporter-2 (SGLT2) inhibitor that removes excess glucose through the urine by blocking glucose reabsorption in the kidney, while metformin decreases the production of glucose in the liver and its absorption in the intestine and improves the body’s ability to utilise glucose.

The firms are hoping that the single tablet approach will boost treatment compliance and help patients better manage the condition.

Synjardy is the third empagliflozin-containing product approved by the FDA thus far. Its label contains a boxed warning for the risk of lactic acidosis, a serious metabolic complication that can occur due to metformin accumulation during treatment with the therapy.

Practice Pearls:

  • Synjardy contains empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin, a biguanide.
  • It is not for the treatment of type 1 diabetes or diabetic ketoacidosis.
  • The drug label contains a boxed warning on the risk of lactic acidosis during treatment with Synjardy.

For more information visit Boehringer-Ingelheim.com or Lilly.com.